CA1177402A - Agents having a tumour-inhibiting action and their use - Google Patents
Agents having a tumour-inhibiting action and their useInfo
- Publication number
- CA1177402A CA1177402A CA000381518A CA381518A CA1177402A CA 1177402 A CA1177402 A CA 1177402A CA 000381518 A CA000381518 A CA 000381518A CA 381518 A CA381518 A CA 381518A CA 1177402 A CA1177402 A CA 1177402A
- Authority
- CA
- Canada
- Prior art keywords
- composition according
- denotes
- diisocyanate
- polyurethane
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/795—Polymers containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/08—Processes
- C08G18/0804—Manufacture of polymers containing ionic or ionogenic groups
- C08G18/0819—Manufacture of polymers containing ionic or ionogenic groups containing anionic or anionogenic groups
- C08G18/0828—Manufacture of polymers containing ionic or ionogenic groups containing anionic or anionogenic groups containing sulfonate groups or groups forming them
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/48—Polyethers
- C08G18/4833—Polyethers containing oxyethylene units
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/48—Polyethers
- C08G18/50—Polyethers having heteroatoms other than oxygen
- C08G18/5072—Polyethers having heteroatoms other than oxygen containing sulfur
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/83—Chemically modified polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/83—Chemically modified polymers
- C08G18/831—Chemically modified polymers by oxygen-containing compounds inclusive of carbonic acid halogenides, carboxylic acid halogenides and epoxy halides
Abstract
Agents having a tumour-inhibiting action and their use Abstract of the Disclosure The invention relates to pharmaceutical compositions containing, as an active ingredient, a water-soluble addition product of a polyether diol and a diisocyanate. The compounds are indicated to be useful as anti-tumour agents. Also included in the invention is the use of said compositions as anti-tumour agents.
Description
~17~;~4~2 -1- Type II (Pha) The present invention relates to the use as agents having a tumour-inhibiting action of water-soluble addition products of a polyether-diol and a diisocyanate~ which are in thsm-selves known.
It has already been disclosed that complex CuII and CoII salts of ethylene/maleic acid copolymers are active against Walker's sarcoma (see J. Med. Chem. 12 (1969), 118û).
Polyoxyethylene sorbitane monooleate ("Tween" 80 -Trade Mark) has already been used for immunisation against hyperdiploid Ehrlich tumour (see Experientia 29 (1973), 710).
Furthermore, polycations of various types, for example polyamidoamines, pbly-N-morpholinoethylacrylamide and N-oxide polymers, have been tested for inhibition of the formation of metastases, with the result that only the dissemination of tumour cells, but not the growth of metastases in situ or metastases in a lymph node, could be influenced (see J. Med. Chem. 16, (1973), 496).
The activity of polymers with carboxyl groups against 180 sarcoma, as a function of the molecular weight, the charge density and also the metal-binding capacity of the carboxyl groups, has also been described (see Dissertation Abstr. Intern. B 33 (1973), 5745).
Polyanions, for example poly-(ammonium acrylate), acrylic ac~d/acrylamide copolymers and also ethylene/
maleic anhydride copolymers are said to have~ in connection with their tumour-inhibiting action, a heparin-like effect and also a virus inhibition, and moreover to increase 30 the immunoreactions [see J. Med. Chem.~17 (1974), 1335].
It is apparent from all this work that the tumour-inhibiting action of the polymers investigated hitherto against the experimental tumours used frequently only lies at the lower limit of significance and, in a Le A 20 3û8 nwnber of cases, is restricted on]y to prophylatic or adjuvant effects. Dis-advantageously, it is moreover apparent that the investigations cited were in many cases carried out on allogenic mouse tumours having a tendency towards spon-taneous regression, and not systematically and under experimental arrangements relevant to clinical conditions. Generally, there is a lack of data on the toxi-city of the preparations, although the administration of high dosages of sub-stances having a high molecular weight of more than 30,000 suggests inadequate elimination, or storage in the tissues.
A block copolymer of polypropylene oxide and polyethylene oxide ~"Pluronic" F 68 - Trade Mark) has proved to be effective against the onset of metastases of Walker's 256 ascites tumour, probably by influencing the ability of the blood to coagulate [see Cancer 29 ~1972), 171]. As is known, these pre-parations are highly active emulsifiers and for this reason are not very well tolerated, in particular on parenteral administration.
W. Regelson et al. [see Nature 186 (1960) 778-780] have investigated the tumour-inhibiting action of synthetic polyelectrolytes, such as polyacrylic acid, polymethacrylic acid and hydrolysed or aminolysed ethylene/maleic anhy-dride copolymers. By comparing the action of the dicarboxylic acid form, the amidocarboxylic acid form and the diamide form of ethylene/maleic anhydride copolymers, they found that at least one ionisable carboxyl group is necessary for a significant tumour inhibition. Experiments carried out by these authors with polyacrylamides in high doses ~800 mg/kg, MW 60-70,000 and 400 mg/kg, MW
120,000) showed a negative tumour-inhibiting action or a non-significant posi-tive twmour-inhibiting action.
Agents having a tumour-inhibiting action have likewise been described, and are characterised in that they contain at least one water-soluble homo-polymer or copolymer .
.~
.
-.
~ :~.1'7~()Z
which contains 1,3-dihydroxy-2-me-thylene-propane and/or derivatives thereof [see DOS (German Published Specification) 2,705,189]. r~ater-soluble homopoly-mers or copolymers which contain 3,4-dihydroxybu~-1-ene orhydroxyalkyl(meth)-acrylate or derivatives thereof, or also derivatives of allyl alcohol, in polymerized or copolymerized form are similar preparations with a similar action [see DOS (German Published Specification) 2,740,082].
It has been found, surprisingly, that the water-soluble addition products, which are in themselves known, of a polyether-diol and a diisocyanate possess strong tumour-inhibi-ting properties.
Surprisingly, in the molecular weight range from 1,000 to 30,000, these substances show significant curative actions against solid tumours of syngenic systems, in a broad dosage range of 0.5 to 500 mg/kg, preferably 5 to 250 mg/kg, under experimental arrangements and methods of administra-tion relevant to clinical conditions. The therapeutic range of the substances thus proves to be unusually wide (LD50 on intravenous administration: >2,500 mg/kg, therapeutic dose: 0.5 to 500 mg/kg). The agents according to the invention thus represent an important enrichment of therapy.
According to the present invention we therefore provide a pharmaceuti-cal composition containing as an active ingredient a water-soluble addition product of a polyetherdiol and a diisocyanate having a molecular weight in the range 1,000 to 30,000, in the form of a sterile and/or physiologically isotonic aqueous solution or in the form of a tablet.
The preferred ingredients for use in the compositions according to the invention are water-soluble oligo-urethanes or polyurethanes of the general formula:
B ~ Q-O-CO-NH-R-N~I-CO ~ Q-O-B
in which Q denotes a polyether radical which optionally contains ionic groups, preferably a radical of the .
;
.
., 79L~Z
-general formula A
~ 0-CH-CH2~n wherein A denotes hydrogen or methyl in random distribution and n is a number from 5 to 500 (preferably from 8 to 3~0), the groups B are identical or difFerent and denote a hydrogen atom` or an aliphatic, alicyclic or aromatic radical with up to 8 carbon atoms (preferablyahydrogen atom or Cl to C4 alkyl group);
a X-C0- group~
in which X denotes a hydrogen atom or an aliphatic, alicyclic or aromatic radical with up to 7 carbon atoms (preferably a hydrogen atom or a Cl to C3 alkyl group~;
a Y-0-C0- group, in which Y denotes an aliphatic, cycloaliphatic or aromatic radical with up to 7 carbon atoms (preferably a ~Cl to C4 alkyl group); or a Z-NH-C0- group~, in which Z denotes a hydrogen atom or an aliphatic, cyclo-aliphatic or aromatic radical with up to 7 carbon atoms (preferably a hydrogen atom or a Cl to C4 alkyl group), -R denotes a bivalent radical oF a diisocyanate~ and m denotes a number from 1 to 30~(preferably from 1 to 15~.
Water-soluble addition products of a polyetherdiol and a diisocyanate which corresponds to the yeneral Formula Le A 20 308 - ' ` ' ' ' `
`
~L~77~q;3~Z
H ~ ~OCH2CH2 ~ 0-CO-NH-R-NH-CO ~;~(OCtl2CH2 ~ 0tl in ~hich R has the abovementioned ~neaning, m denotes a number from 1 to 30 and n denotes a number from 5 to 500, are particularly suitable as active ingredients for the compositions according to the invention.
Diisocyanates which are particularly suitable for the preparation of the addition products used according to the invention are hexamethylene diiso-1~ cyc~late and isophorone diisocyanate.
In a particular embodiment of the invention, the polyaddition com-pounds used as active ingredients contain ionic groups (such as carboxyl groups or, preferably, sulphonate groups). It is expedient for these ionic groups to be introduced into the polyaddition compounds by using or co-using diols which carry the desired groups. Thus, for example, the diol of the formula H-(O-CH2CH2 ~ O-CH2-CH-CH2-CH2-O~CH2-CH2-O ~ H
S03Na can be employed for the preparation of an active compound carrying ionic groups.
Examples of water-soluble polyaddition compounds which are to be used according to the invention are:
tl-~--(OCH2Ctl2 ~ o_coNH-~CH2)6-NHCO ~ ~ocH2cH2 ~ OH ~I) H~ OCtl2Ctl2 ~ O-CONH-~CH2)6-NHCO ~ ~OCH2CH2 ~ OH ~II) H-~-(OCH2CH2 ~ O-CONH-(CH2)6-NHCO ~ (CH2CH2 ~ OH ~III) H-~-~ocH2cH2~---O-CONH-~cH2)6-NHCO ~ ~ocH2cH2~ oH ~IV) H-t--~OCH2CH2~--- O-CONH-~CH2)6-NHCO~ OCH2CH2~ OH ~V) ~r -6- ~ 2 H ~ ~OCH2CH2~ O- CONII- (CH2) 6-NHCO ~ (CH2CH2~ OH (VI) H~(OCH2C~12~ O-CO-HN- ~ 2 4 35 (VII) H--~OCH2CH2~ O-COHN-H[~ CH2 2 68 (VIII) H~(ocH2cH~t O-COHN- ~ 2 2 35 (IX) 3,~<~ 3 35 CH3-NHco~(ocH2cH2~oH (X) H~ (CH2CH2~ O-COHN- ~< CH3-NHCO~(OCH2CH~OH (XI) H~(OcH2cH2~ O-CO-HN- ~ CH3-NHCO~(OC~12CH2~8 OH (XII) X
` . ~ ~ ~ , ,` .
.
7_ ~77~
C113 C~13 H ~ ( CH2 CH2~ 0Ctl2 - fl- CH2- CH2- O- (CH2 CH2 - 03--CNH- ~!~ cC~123 S03Na _ ~XI I I) _ lNH-CO~(OC}I2CH2~O-CH2-fI-CH2-CH2 ( 2 2 7 S03Na ~( f 2~3 OCH2-ICH-CH2-CtI2-O-~CH2CH-O~CONH-~CHH23 CH3 SO3Na CH3 ~XIV) LNH-CO~ ~CHCH2~ Ctl2-CH-CH2-CH2-O ~CH2CIH OtH
CH3 SO3Na CH3 The water-soluble polyaddition products which represent the active com-pounds according to the invention are prepared by processes wh:ich are in them-selves known. They are obtained by reacting polyether-glycols which have vari-ous chain lengths and can optionally contain ionic groups, such as sulphonate groups, carboxylate groups or ammonium groups, with diisocyanates, in particular with hexamethylene diisocyanate or isophorone diisocyanate.
These reactions are carried out in an inert solvent, such as, prefer-ably, chloroform or methylene chloride. The ratio of diol to diisocyanate is chosen such that molecule chains greater or shorter in length result, in a con-trolled manner. Less than the equivalent amount of diisocyanate is always employed, so that polymers with OH end groups are formed. The reaction tempera-ture is room temperature to the boiling point of the solvent. The reaction time is 2 to 8 hours.
.
-8- ~ 40~
The hydroxyl end groups of the oligo-urethanes or polyurethanes can be converted into ether groups, carboxylic acid ester groups, carbonic acid ester groups or urethane groups by known methods.
Examples which may be mentioned of alkylating agents for etherifying the hydroxyl groups are dialkyl sulphates, alkyl halides and esters of p-toluene-sulphonic acid .
7~QZ
, g [see Organikum, Oryanisch-chemisches Grundpraktikum (Basic Manual of Organic Chemistry), 6th edition, Berlin 1967, pages 185 et seq.]. Carboxylic acid ester groups can be introduced, for example, by the action of acid anhydrides in the presence of an acid catalyst or by reactionlwith acid chlorides in the presence of a tertiary amine. Carbonic acid ester,,groups can be produced by reaction with chloroformic acid estersin the presence of inert bases.
If mixtures of diisocyanates and monoisocyanates are employed in the preparation of the polyurethane, products with urethane end groups are obtained.
When the reaction has ended, the solvent is removed, preferably by being distilled off,in vacuo.
Liquid or viscous to solid substances are obtained, which can be characterised by their melting point or their refractive index and which are soluble in water or in physiological sodium chloride solution, in some cases with a slight cloudiness, to give solutions of at least 2û 0.5 ~ strength by weight.
In addition to an exceptionally low toxicity, the agents according to the invention have a strong tumour-inhibiting action against tumours in animals and humans and are therefore intended for use in combating illnesses caused by tumours.
The agents according to the invention are prepared by dissolving the active compounds in physiological sodium chloride solution.
As stated above, the invention also relates to the use in human and veterinary medicine as antitumorial ag,ents of the compounds of the invention.
This invention further provides a method of combating (including prevention, relief and cure of) the above-mentioned diseases in human and non-human animals, which Le A 20 308 ~'7~7~
comprises administering to the animals a compound of the invention in admixture with a diluent. For parenteral administration such solutions should be sterile and; if appropriate blood isotonic.
It is envisaged that these active compounds will be administered parenterally (for example intramuscularly, intraperitoneally, subcutaneously and intravenously)-systemically or locally-preferably intraperitoneally, intraven-ously or intramuscularly. Preferred pharmaceutical compositions and medicaments are therefore those adapted for administration such as intraperitoneal, intraven-ous or intramuscular administration. Administration in the method of the inven-tion is preferably intraperitoneal, intravenous or intramuscular administration.~lowever, peroral administration is possible, too.
In general it has proved advantageous to administer amounts of from 0.5 mg to 500 mg/kg, preferably 5 mg to 250 mg/kg, of body weight per day to achieve effective results. Nevertheless, it can at times be neccssary to devi-ate from those dosage rates, and in particular to do so as a function of the nature and body weight of the human or animal subject to be treated, the indivi-dual reaction of this subject to the treatment, the type of fGrmulation in which the active ingredient is administered and the mode in which the administration is carried out, and ~he point in the progress of the disease or interval at which it is to be administered. Thus it may in some cases suffice to use less than the above-mentioned minimum dosage rate, whilst in other cases the upper limit mentioned must be exceeded to achieve the desired results. Where larger amounts are administered it can be advisable to divide these into several indivi-dual administrations over the course of the day.
The unusual breadth of the abovementioned therapeutic dosage range is based on the unusual non-toxicity of the active compounds.
The substances listed in Table 1 were tested for this induction of ~17~4~2 tumour-inhibiting action on mouse sarcoma MCS 4 and on carcinoma EO 771 in numerous experiments, under various test conditions.
The method of the investigations on these two experimental tumours are given in the following experimental descriptions (a) and ~b).
Description of experiments a?
Tumour tests against carcinoma E0 771 in C 57 BL/6 mice _ _ _ . _ _ _ _ Animal strain: C 57 BL/6 mice, inbred (SPF) Methods:
Maintaining the tumour strain: 14-20 days after -the last transplantation, sub-cutaneous inoculation of a suspension of cells of carcinoma E0 771 in 0.5 ml of 0.9 % phosphate-buffered NaCl solution (PBS) into C 57 BL/6 mice.
Preparation of screening tests: Same process as in maintaining the strain of the tumour, but subcutaneous inoculation of a suspension of 5 x 104 tumour cells in 0.5 ml of 0.9 % PBS.
Treatment: Single intramuscular injection of the required solution of the sub-stances 6 days prior to or 2 days after the tumour transplantation.
Duration of experiments: 18-22 days after the tumour transpla;ltation. There-after, sacrificing of the animals, preparation and weighing of the subcutaneous tumours.
Evaluation parameters: Inhibition of the tumour growth by determination of the average tumour weight of control animals and groups of treated ~nimals, as well as calculation of the tumour weight (TW) index according to the formula:
Tl~ index = 0 tumour weight of the groups of treated animals ~ tumour weight of the control group Assessment of the test results:
n~ index 0.8 - 0.6 = marginal activity 0.6 - 0.4 = moderate activity 0.4 - 0.0 = good activity X
77~
Description of experiments b) Tumour tests against sarcoma MCS 4 in C 57 BL!6 mice Malntaining the tumour strain: 10-14 days after the last transplantation, sub-cutaneous inoculation of a suspension of cells of sarcoma MCS 4 in 0.5 ml of 0.9 % phosphate-buffered NaCl solution (PBS) into C 57 BL/6 mice.
Preparation of screening tests: Same process as in maintaining the strain of the tumour, but subcutaneous inoculation of a suspension of 2 x 105 tumour cells in 0.5 ml of 0.9 % PBS.
Treatment: Single intravenous injection of the required solution of substances
It has already been disclosed that complex CuII and CoII salts of ethylene/maleic acid copolymers are active against Walker's sarcoma (see J. Med. Chem. 12 (1969), 118û).
Polyoxyethylene sorbitane monooleate ("Tween" 80 -Trade Mark) has already been used for immunisation against hyperdiploid Ehrlich tumour (see Experientia 29 (1973), 710).
Furthermore, polycations of various types, for example polyamidoamines, pbly-N-morpholinoethylacrylamide and N-oxide polymers, have been tested for inhibition of the formation of metastases, with the result that only the dissemination of tumour cells, but not the growth of metastases in situ or metastases in a lymph node, could be influenced (see J. Med. Chem. 16, (1973), 496).
The activity of polymers with carboxyl groups against 180 sarcoma, as a function of the molecular weight, the charge density and also the metal-binding capacity of the carboxyl groups, has also been described (see Dissertation Abstr. Intern. B 33 (1973), 5745).
Polyanions, for example poly-(ammonium acrylate), acrylic ac~d/acrylamide copolymers and also ethylene/
maleic anhydride copolymers are said to have~ in connection with their tumour-inhibiting action, a heparin-like effect and also a virus inhibition, and moreover to increase 30 the immunoreactions [see J. Med. Chem.~17 (1974), 1335].
It is apparent from all this work that the tumour-inhibiting action of the polymers investigated hitherto against the experimental tumours used frequently only lies at the lower limit of significance and, in a Le A 20 3û8 nwnber of cases, is restricted on]y to prophylatic or adjuvant effects. Dis-advantageously, it is moreover apparent that the investigations cited were in many cases carried out on allogenic mouse tumours having a tendency towards spon-taneous regression, and not systematically and under experimental arrangements relevant to clinical conditions. Generally, there is a lack of data on the toxi-city of the preparations, although the administration of high dosages of sub-stances having a high molecular weight of more than 30,000 suggests inadequate elimination, or storage in the tissues.
A block copolymer of polypropylene oxide and polyethylene oxide ~"Pluronic" F 68 - Trade Mark) has proved to be effective against the onset of metastases of Walker's 256 ascites tumour, probably by influencing the ability of the blood to coagulate [see Cancer 29 ~1972), 171]. As is known, these pre-parations are highly active emulsifiers and for this reason are not very well tolerated, in particular on parenteral administration.
W. Regelson et al. [see Nature 186 (1960) 778-780] have investigated the tumour-inhibiting action of synthetic polyelectrolytes, such as polyacrylic acid, polymethacrylic acid and hydrolysed or aminolysed ethylene/maleic anhy-dride copolymers. By comparing the action of the dicarboxylic acid form, the amidocarboxylic acid form and the diamide form of ethylene/maleic anhydride copolymers, they found that at least one ionisable carboxyl group is necessary for a significant tumour inhibition. Experiments carried out by these authors with polyacrylamides in high doses ~800 mg/kg, MW 60-70,000 and 400 mg/kg, MW
120,000) showed a negative tumour-inhibiting action or a non-significant posi-tive twmour-inhibiting action.
Agents having a tumour-inhibiting action have likewise been described, and are characterised in that they contain at least one water-soluble homo-polymer or copolymer .
.~
.
-.
~ :~.1'7~()Z
which contains 1,3-dihydroxy-2-me-thylene-propane and/or derivatives thereof [see DOS (German Published Specification) 2,705,189]. r~ater-soluble homopoly-mers or copolymers which contain 3,4-dihydroxybu~-1-ene orhydroxyalkyl(meth)-acrylate or derivatives thereof, or also derivatives of allyl alcohol, in polymerized or copolymerized form are similar preparations with a similar action [see DOS (German Published Specification) 2,740,082].
It has been found, surprisingly, that the water-soluble addition products, which are in themselves known, of a polyether-diol and a diisocyanate possess strong tumour-inhibi-ting properties.
Surprisingly, in the molecular weight range from 1,000 to 30,000, these substances show significant curative actions against solid tumours of syngenic systems, in a broad dosage range of 0.5 to 500 mg/kg, preferably 5 to 250 mg/kg, under experimental arrangements and methods of administra-tion relevant to clinical conditions. The therapeutic range of the substances thus proves to be unusually wide (LD50 on intravenous administration: >2,500 mg/kg, therapeutic dose: 0.5 to 500 mg/kg). The agents according to the invention thus represent an important enrichment of therapy.
According to the present invention we therefore provide a pharmaceuti-cal composition containing as an active ingredient a water-soluble addition product of a polyetherdiol and a diisocyanate having a molecular weight in the range 1,000 to 30,000, in the form of a sterile and/or physiologically isotonic aqueous solution or in the form of a tablet.
The preferred ingredients for use in the compositions according to the invention are water-soluble oligo-urethanes or polyurethanes of the general formula:
B ~ Q-O-CO-NH-R-N~I-CO ~ Q-O-B
in which Q denotes a polyether radical which optionally contains ionic groups, preferably a radical of the .
;
.
., 79L~Z
-general formula A
~ 0-CH-CH2~n wherein A denotes hydrogen or methyl in random distribution and n is a number from 5 to 500 (preferably from 8 to 3~0), the groups B are identical or difFerent and denote a hydrogen atom` or an aliphatic, alicyclic or aromatic radical with up to 8 carbon atoms (preferablyahydrogen atom or Cl to C4 alkyl group);
a X-C0- group~
in which X denotes a hydrogen atom or an aliphatic, alicyclic or aromatic radical with up to 7 carbon atoms (preferably a hydrogen atom or a Cl to C3 alkyl group~;
a Y-0-C0- group, in which Y denotes an aliphatic, cycloaliphatic or aromatic radical with up to 7 carbon atoms (preferably a ~Cl to C4 alkyl group); or a Z-NH-C0- group~, in which Z denotes a hydrogen atom or an aliphatic, cyclo-aliphatic or aromatic radical with up to 7 carbon atoms (preferably a hydrogen atom or a Cl to C4 alkyl group), -R denotes a bivalent radical oF a diisocyanate~ and m denotes a number from 1 to 30~(preferably from 1 to 15~.
Water-soluble addition products of a polyetherdiol and a diisocyanate which corresponds to the yeneral Formula Le A 20 308 - ' ` ' ' ' `
`
~L~77~q;3~Z
H ~ ~OCH2CH2 ~ 0-CO-NH-R-NH-CO ~;~(OCtl2CH2 ~ 0tl in ~hich R has the abovementioned ~neaning, m denotes a number from 1 to 30 and n denotes a number from 5 to 500, are particularly suitable as active ingredients for the compositions according to the invention.
Diisocyanates which are particularly suitable for the preparation of the addition products used according to the invention are hexamethylene diiso-1~ cyc~late and isophorone diisocyanate.
In a particular embodiment of the invention, the polyaddition com-pounds used as active ingredients contain ionic groups (such as carboxyl groups or, preferably, sulphonate groups). It is expedient for these ionic groups to be introduced into the polyaddition compounds by using or co-using diols which carry the desired groups. Thus, for example, the diol of the formula H-(O-CH2CH2 ~ O-CH2-CH-CH2-CH2-O~CH2-CH2-O ~ H
S03Na can be employed for the preparation of an active compound carrying ionic groups.
Examples of water-soluble polyaddition compounds which are to be used according to the invention are:
tl-~--(OCH2Ctl2 ~ o_coNH-~CH2)6-NHCO ~ ~ocH2cH2 ~ OH ~I) H~ OCtl2Ctl2 ~ O-CONH-~CH2)6-NHCO ~ ~OCH2CH2 ~ OH ~II) H-~-(OCH2CH2 ~ O-CONH-(CH2)6-NHCO ~ (CH2CH2 ~ OH ~III) H-~-~ocH2cH2~---O-CONH-~cH2)6-NHCO ~ ~ocH2cH2~ oH ~IV) H-t--~OCH2CH2~--- O-CONH-~CH2)6-NHCO~ OCH2CH2~ OH ~V) ~r -6- ~ 2 H ~ ~OCH2CH2~ O- CONII- (CH2) 6-NHCO ~ (CH2CH2~ OH (VI) H~(OCH2C~12~ O-CO-HN- ~ 2 4 35 (VII) H--~OCH2CH2~ O-COHN-H[~ CH2 2 68 (VIII) H~(ocH2cH~t O-COHN- ~ 2 2 35 (IX) 3,~<~ 3 35 CH3-NHco~(ocH2cH2~oH (X) H~ (CH2CH2~ O-COHN- ~< CH3-NHCO~(OCH2CH~OH (XI) H~(OcH2cH2~ O-CO-HN- ~ CH3-NHCO~(OC~12CH2~8 OH (XII) X
` . ~ ~ ~ , ,` .
.
7_ ~77~
C113 C~13 H ~ ( CH2 CH2~ 0Ctl2 - fl- CH2- CH2- O- (CH2 CH2 - 03--CNH- ~!~ cC~123 S03Na _ ~XI I I) _ lNH-CO~(OC}I2CH2~O-CH2-fI-CH2-CH2 ( 2 2 7 S03Na ~( f 2~3 OCH2-ICH-CH2-CtI2-O-~CH2CH-O~CONH-~CHH23 CH3 SO3Na CH3 ~XIV) LNH-CO~ ~CHCH2~ Ctl2-CH-CH2-CH2-O ~CH2CIH OtH
CH3 SO3Na CH3 The water-soluble polyaddition products which represent the active com-pounds according to the invention are prepared by processes wh:ich are in them-selves known. They are obtained by reacting polyether-glycols which have vari-ous chain lengths and can optionally contain ionic groups, such as sulphonate groups, carboxylate groups or ammonium groups, with diisocyanates, in particular with hexamethylene diisocyanate or isophorone diisocyanate.
These reactions are carried out in an inert solvent, such as, prefer-ably, chloroform or methylene chloride. The ratio of diol to diisocyanate is chosen such that molecule chains greater or shorter in length result, in a con-trolled manner. Less than the equivalent amount of diisocyanate is always employed, so that polymers with OH end groups are formed. The reaction tempera-ture is room temperature to the boiling point of the solvent. The reaction time is 2 to 8 hours.
.
-8- ~ 40~
The hydroxyl end groups of the oligo-urethanes or polyurethanes can be converted into ether groups, carboxylic acid ester groups, carbonic acid ester groups or urethane groups by known methods.
Examples which may be mentioned of alkylating agents for etherifying the hydroxyl groups are dialkyl sulphates, alkyl halides and esters of p-toluene-sulphonic acid .
7~QZ
, g [see Organikum, Oryanisch-chemisches Grundpraktikum (Basic Manual of Organic Chemistry), 6th edition, Berlin 1967, pages 185 et seq.]. Carboxylic acid ester groups can be introduced, for example, by the action of acid anhydrides in the presence of an acid catalyst or by reactionlwith acid chlorides in the presence of a tertiary amine. Carbonic acid ester,,groups can be produced by reaction with chloroformic acid estersin the presence of inert bases.
If mixtures of diisocyanates and monoisocyanates are employed in the preparation of the polyurethane, products with urethane end groups are obtained.
When the reaction has ended, the solvent is removed, preferably by being distilled off,in vacuo.
Liquid or viscous to solid substances are obtained, which can be characterised by their melting point or their refractive index and which are soluble in water or in physiological sodium chloride solution, in some cases with a slight cloudiness, to give solutions of at least 2û 0.5 ~ strength by weight.
In addition to an exceptionally low toxicity, the agents according to the invention have a strong tumour-inhibiting action against tumours in animals and humans and are therefore intended for use in combating illnesses caused by tumours.
The agents according to the invention are prepared by dissolving the active compounds in physiological sodium chloride solution.
As stated above, the invention also relates to the use in human and veterinary medicine as antitumorial ag,ents of the compounds of the invention.
This invention further provides a method of combating (including prevention, relief and cure of) the above-mentioned diseases in human and non-human animals, which Le A 20 308 ~'7~7~
comprises administering to the animals a compound of the invention in admixture with a diluent. For parenteral administration such solutions should be sterile and; if appropriate blood isotonic.
It is envisaged that these active compounds will be administered parenterally (for example intramuscularly, intraperitoneally, subcutaneously and intravenously)-systemically or locally-preferably intraperitoneally, intraven-ously or intramuscularly. Preferred pharmaceutical compositions and medicaments are therefore those adapted for administration such as intraperitoneal, intraven-ous or intramuscular administration. Administration in the method of the inven-tion is preferably intraperitoneal, intravenous or intramuscular administration.~lowever, peroral administration is possible, too.
In general it has proved advantageous to administer amounts of from 0.5 mg to 500 mg/kg, preferably 5 mg to 250 mg/kg, of body weight per day to achieve effective results. Nevertheless, it can at times be neccssary to devi-ate from those dosage rates, and in particular to do so as a function of the nature and body weight of the human or animal subject to be treated, the indivi-dual reaction of this subject to the treatment, the type of fGrmulation in which the active ingredient is administered and the mode in which the administration is carried out, and ~he point in the progress of the disease or interval at which it is to be administered. Thus it may in some cases suffice to use less than the above-mentioned minimum dosage rate, whilst in other cases the upper limit mentioned must be exceeded to achieve the desired results. Where larger amounts are administered it can be advisable to divide these into several indivi-dual administrations over the course of the day.
The unusual breadth of the abovementioned therapeutic dosage range is based on the unusual non-toxicity of the active compounds.
The substances listed in Table 1 were tested for this induction of ~17~4~2 tumour-inhibiting action on mouse sarcoma MCS 4 and on carcinoma EO 771 in numerous experiments, under various test conditions.
The method of the investigations on these two experimental tumours are given in the following experimental descriptions (a) and ~b).
Description of experiments a?
Tumour tests against carcinoma E0 771 in C 57 BL/6 mice _ _ _ . _ _ _ _ Animal strain: C 57 BL/6 mice, inbred (SPF) Methods:
Maintaining the tumour strain: 14-20 days after -the last transplantation, sub-cutaneous inoculation of a suspension of cells of carcinoma E0 771 in 0.5 ml of 0.9 % phosphate-buffered NaCl solution (PBS) into C 57 BL/6 mice.
Preparation of screening tests: Same process as in maintaining the strain of the tumour, but subcutaneous inoculation of a suspension of 5 x 104 tumour cells in 0.5 ml of 0.9 % PBS.
Treatment: Single intramuscular injection of the required solution of the sub-stances 6 days prior to or 2 days after the tumour transplantation.
Duration of experiments: 18-22 days after the tumour transpla;ltation. There-after, sacrificing of the animals, preparation and weighing of the subcutaneous tumours.
Evaluation parameters: Inhibition of the tumour growth by determination of the average tumour weight of control animals and groups of treated ~nimals, as well as calculation of the tumour weight (TW) index according to the formula:
Tl~ index = 0 tumour weight of the groups of treated animals ~ tumour weight of the control group Assessment of the test results:
n~ index 0.8 - 0.6 = marginal activity 0.6 - 0.4 = moderate activity 0.4 - 0.0 = good activity X
77~
Description of experiments b) Tumour tests against sarcoma MCS 4 in C 57 BL!6 mice Malntaining the tumour strain: 10-14 days after the last transplantation, sub-cutaneous inoculation of a suspension of cells of sarcoma MCS 4 in 0.5 ml of 0.9 % phosphate-buffered NaCl solution (PBS) into C 57 BL/6 mice.
Preparation of screening tests: Same process as in maintaining the strain of the tumour, but subcutaneous inoculation of a suspension of 2 x 105 tumour cells in 0.5 ml of 0.9 % PBS.
Treatment: Single intravenous injection of the required solution of substances
2 days prior to or 2 days after the tumour transplantation.
Duration of experiments: 18-22 days after the tumour transplantation. There-after, sacrificing of the animals~ preparation and weighing of the tumours.
Evaluation and assessment of the results are carried out analogously to the des--cription of experiments a).
Overall assessment of the results in Tables 1 and 2 The tumour weight indices of the preparations listed in Tables 1 and 2 show that the substances at various doses, by various methods of administration, and also on various days of treatment are capable of inducing distinct tumour--inhibiting activity both against sarcoma MCS 4 and against carcinoma EO 771.
~17~
X , X
~ ~:~
. ., ~O
rl ~rl ~. . a~ . . . . . .
Duration of experiments: 18-22 days after the tumour transplantation. There-after, sacrificing of the animals~ preparation and weighing of the tumours.
Evaluation and assessment of the results are carried out analogously to the des--cription of experiments a).
Overall assessment of the results in Tables 1 and 2 The tumour weight indices of the preparations listed in Tables 1 and 2 show that the substances at various doses, by various methods of administration, and also on various days of treatment are capable of inducing distinct tumour--inhibiting activity both against sarcoma MCS 4 and against carcinoma EO 771.
~17~
X , X
~ ~:~
. ., ~O
rl ~rl ~. . a~ . . . . . .
3 o o 3 O o o o o o o o El * 0~` o ~ ~ ~ ~
;i h~J ~ ~ h ~D c~ D ~1 ~ 1 V ~1 I + O ~ I ~ I + I + I + h O E O h o o P~ ___ o h ~ ~ $:~ - . ~ .
O o O ~ h h h h L~ ~ ~. a) ,1 +~ ~1 ~ ~ 0 t~ 0 t~ h h ~ ~ ~ ~ ~ ~ ~ qo~ $
~,~ S~ O O ~,~ h ~ o c) o o ~H
X ~ ~ ~ ~ X ~ ~ ~d u~ a~ ~ ~ ~a ~
~d ~ ~ ~ ~ ~ ~ ~ ~
v~ ,1 h h u~ ,1 h h h h. h h ~ ~ t~ t~
~ ~ ~ ~ ~ ~ ~ ~d ~
~ ~ ~ 1 ~ '1 r~ ~1 ~1 ~ rl rl r~ rl a) a) .
a) ~ h O
~q ~ IS~ ~ ~Q ~ IS~
~q O b~ ~ O ~ I +
o ~ a~ ~ ~ ~ o ~ o o o o o E~ _ E~ . ~
~
- - o ~l ~
~ ~ l ~
~ ~ ~ c~ ~ ~ ~o o- ~- o- x x ~ x o~; H o~Z ~, _ H
~ V X ~ ~ H H H X
E-l . _ _ E-l _ ~ ~ H *
Le A 20 308 .
-14- ~77~Z
The following Examples illustrate the production of active ingredients used in the compositions of the present invention.
Example 1 Water-soluble polyurethane of the formula (I) H~¦OCH2CH2~0-CO-NH-~CH2)6-NH-CO~(OC~l2cH2~0H
A solution of 50.5 parts by weight of a polyglycol with an average molecular weight of 1,000 in 50 parts by volume of chloroform was initially introduced into a closed three-necked stirred apparatus which was equipped with a thermometer, dropping f~mnel and reflux condenser. A solution of 6.7 parts by weight of hexamethylene diisocyanate in 50 parts by volume of chloroform was added dropwise, whilst stirring continuously. After subsequently stirring the mixture at 50C for 2 hours, the solvent was evaporated off in a rotary evapo-rator. A crystalline water-soluble substance was obtained. Melting point: 42 C.
Example 2 Polyurethane of the formula ~II) H-~-~OCH2CH2~--0-CO-NH-(CH2)6-NH-CO~ OCH2CH2~--OH
A solution of 6.7 parts by weight of hexamethylene diisocyanate in 50 parts by volume of chloroform was added to 15 parts by weight of a polyglycol with an average molecular weight of 300, dissolved in 50 parts by volume of chloroform, as described in Example 1. The mixture was allowed to react com-pletely at 50C by stirring for 2 hours, and~ finally, the solvent was stripped off in a rotary evaporator. A viscous, water-soluble liquid with a refractive index nD of 1.4876 resulted.
Example 3 Polyurethane of the formula H~ OCH2CH2 t 0-CO-NH-~CH2~6-NH-CO-}~-~OcH2cH2~---- OH
g~77~(1Z
20 parts by weight of a polyglycol with an average molecular weight of about 400 were reac~ed with 6.7 parts by weight of hexamethylene diisocyanate in chloroform, analogously to Example 1. A viscous liquid which was readily water--soluble and had a refractive index nD of 1.4850 was obtained.
Example 4 Polyurethane of the formula ~VI) H-~-(OCH2CH2~----- o-CO-NH-(CH2)6-NH-CO-~--(OC~12CH2~---OH
150 parts by weight of a polyglycol with an average molecular weight of 3,000 were reacted with 6.7 parts by weight of hexamethylene diisocyanate in methylene chloride, as described in Example 1. After evaporating off the solvent, a crystalline substance which was soluble in water, giving a slightly turbid solution, was obtained. Melting point: m.p. = 53C.
Example 5 Polyurethane of the formula H-~-~OCH2CH21--- O-co-NH-(cH2)6-NH-co-~ ocH2cH2l--- OH
A water-soluble crystalline substance with a melting point m.p. of 45 C was obtained by reacting 77.5 parts by weight of a polyglycol with an aver-age molecular weight of 1,550 with 6.7 parts by weight of hexamethylene diiso-cyanate.
Example 6 Polyurethane of the formula H-~-(OCH2CH2~----O-CO-NH- ~ CH3-N~I-CO-~--(OCH2CH2~0H
A solution of 8.9 parts by weight of isophorone diisocyanate in 50 parts by volume of chloroform was added to a solution of 15 parts by weight of a ~.77~02 polyglycol with an average molecular weight of 300 in 50 parts by volume of chloroform, analogously to Example 1. After subsequently stirring the mixture a~ 50C for 2 hours, the chloroform was evaporated off in a rotary evaporator.
A slightly viscous liquid which was very readily soluble in water was obtained.
Refractive index nD = 1.4952.
Example 7 Polyurethane of the formula (VII) >~
~12Cl~2~ -C-NH- U C 2 4 35 77.5 parts by weight of a polyglycol with an average molecu~ar weight of 1,550 were reacted with 8.9 parts by weight of isophorone diisocyanate analo-gously to Example 1. The resulting polyurethane was a crystalline substance, which was readily soluble in water to give a 10 % strength solution. Melting point: m.p. = 56C.
Example 8 Polyurethane of the formula (OCH2CH2~ o-co-NH- ~ c 2 4 2 68 A polyurethane which was soluble in water, giving a slightly turbid solution, and has a melting point m.p. of 47 C was obtained from 150 parts by weight of a polyglycol with an average molecular weight of 3,000 and 8.9 parts by weight of isophorone diisocyanate.
Example 9 Polyurethane of the formula -17- ~77402 Cil3 C113 (0c~l2cll2~-O-Co-NH- ~ CH2 2 2 2 68 102 parts by weight of a polyglycol with an average molecular weight of 3,000 were reacted with 5 parts by weight of isophorone diisocyanate as des-cribed in Example l. A crystalline substance which was very readily soluble in water and had a melting point m.p. of 54C was obtained.
Example 10 Polyurethane of the formula (XI) ~l ~ l3 H-~-~OCH2CH2~ 0-C0-NH- ~ 2 7 7 A slightly viscous li~uid which was readily soluble in water and had a refractive index nD of 1.4968 was obtained by reacting 24 parts by weight of a polyglycol with an average molecular weight of 300 with 15.5 parts by weight of isophorone diisocyanate in chloroform and evaporating off the solvent in a rotary evaporator.
Example 11 Polyurethane of the formula ~1 ~ (oc~l2cH2~ O-cO-NH-~c~l2)6-NH-co-t~-~ocH2cH2~ OH
After reacting 120 parts by weight of a polyglycol with an average molecular weight of 3,000 with 4.5 parts by weight of hexamethylene diisocyanate in methylene chloride, and after evaporating off the solvent in vacuo, a crystal-line substance which was readily soluble in water and had a melting point m.p.of 55C was obtained.
Example 12 Polyurethane of the formula ~IX) , .
-18- 1~4~
(OCH2cil2~---o-co-NH- ~ 2 2 35 93 parts by weight of a polyglycol with an average molecular weight of 1,550 and 8.9 parts by weight of isophorone diisocyanate were reacted with one another in chloroform. After evaporating off the solvent in vacuo, a crystal-line substance which was readily soluble in water was obtained. Malting point:
m.p. = 49C.
Example 13 Polyurethane of the formula ~X) H-(OCH2CH2~--- O-CO-NH- ~ CHH3-NH-CO-(OCH2CH2- } OH
124 parts by weight of a polyglycol with an average molecular weight of 1,550 and 8.9 parts by weight of isophorone diisocyanate were reacted with one another in chloroform. After evaporating off the solvent, a crystalline sub-stance which could readily be dissolved in water was obtained. Melting point:
m.p. - 56C.
Example 14 Polyurethane of the formula (XIV) H-~-(OCI~I-C~12~--0CH2-CH-CH2-CH2-0-(CH2CH-O~--CONH- ~ CH23 CH3 S03Na CH3 . _ lNH-CO ~ (OCHCH2 ~ 0-CH2-CIH-CH2-CH2 O-(CH2C~I-O ~ H
CH3 S03Na CH3 -19- ~774VZ
254 parts by weight of the sulphonate-diol of the formula H-(OCHCH23-- 0CH2-CH-CH2-CH2-0-~
CH3 S03Na CH3 were dissolved in 500 parts by volume of toluene, and the solution was warmed tothe reflux temperature. 83 parts by weight of isophorone diisocyanate were then added slowly. After subsequently stirring the mixture for 2 hours, the toluene was distilled off in vacuo. A crystalline substance which was readily soluble in water was obtained.
,d~
' ' ' ~ ' ' "'' -
;i h~J ~ ~ h ~D c~ D ~1 ~ 1 V ~1 I + O ~ I ~ I + I + I + h O E O h o o P~ ___ o h ~ ~ $:~ - . ~ .
O o O ~ h h h h L~ ~ ~. a) ,1 +~ ~1 ~ ~ 0 t~ 0 t~ h h ~ ~ ~ ~ ~ ~ ~ qo~ $
~,~ S~ O O ~,~ h ~ o c) o o ~H
X ~ ~ ~ ~ X ~ ~ ~d u~ a~ ~ ~ ~a ~
~d ~ ~ ~ ~ ~ ~ ~ ~
v~ ,1 h h u~ ,1 h h h h. h h ~ ~ t~ t~
~ ~ ~ ~ ~ ~ ~ ~d ~
~ ~ ~ 1 ~ '1 r~ ~1 ~1 ~ rl rl r~ rl a) a) .
a) ~ h O
~q ~ IS~ ~ ~Q ~ IS~
~q O b~ ~ O ~ I +
o ~ a~ ~ ~ ~ o ~ o o o o o E~ _ E~ . ~
~
- - o ~l ~
~ ~ l ~
~ ~ ~ c~ ~ ~ ~o o- ~- o- x x ~ x o~; H o~Z ~, _ H
~ V X ~ ~ H H H X
E-l . _ _ E-l _ ~ ~ H *
Le A 20 308 .
-14- ~77~Z
The following Examples illustrate the production of active ingredients used in the compositions of the present invention.
Example 1 Water-soluble polyurethane of the formula (I) H~¦OCH2CH2~0-CO-NH-~CH2)6-NH-CO~(OC~l2cH2~0H
A solution of 50.5 parts by weight of a polyglycol with an average molecular weight of 1,000 in 50 parts by volume of chloroform was initially introduced into a closed three-necked stirred apparatus which was equipped with a thermometer, dropping f~mnel and reflux condenser. A solution of 6.7 parts by weight of hexamethylene diisocyanate in 50 parts by volume of chloroform was added dropwise, whilst stirring continuously. After subsequently stirring the mixture at 50C for 2 hours, the solvent was evaporated off in a rotary evapo-rator. A crystalline water-soluble substance was obtained. Melting point: 42 C.
Example 2 Polyurethane of the formula ~II) H-~-~OCH2CH2~--0-CO-NH-(CH2)6-NH-CO~ OCH2CH2~--OH
A solution of 6.7 parts by weight of hexamethylene diisocyanate in 50 parts by volume of chloroform was added to 15 parts by weight of a polyglycol with an average molecular weight of 300, dissolved in 50 parts by volume of chloroform, as described in Example 1. The mixture was allowed to react com-pletely at 50C by stirring for 2 hours, and~ finally, the solvent was stripped off in a rotary evaporator. A viscous, water-soluble liquid with a refractive index nD of 1.4876 resulted.
Example 3 Polyurethane of the formula H~ OCH2CH2 t 0-CO-NH-~CH2~6-NH-CO-}~-~OcH2cH2~---- OH
g~77~(1Z
20 parts by weight of a polyglycol with an average molecular weight of about 400 were reac~ed with 6.7 parts by weight of hexamethylene diisocyanate in chloroform, analogously to Example 1. A viscous liquid which was readily water--soluble and had a refractive index nD of 1.4850 was obtained.
Example 4 Polyurethane of the formula ~VI) H-~-(OCH2CH2~----- o-CO-NH-(CH2)6-NH-CO-~--(OC~12CH2~---OH
150 parts by weight of a polyglycol with an average molecular weight of 3,000 were reacted with 6.7 parts by weight of hexamethylene diisocyanate in methylene chloride, as described in Example 1. After evaporating off the solvent, a crystalline substance which was soluble in water, giving a slightly turbid solution, was obtained. Melting point: m.p. = 53C.
Example 5 Polyurethane of the formula H-~-~OCH2CH21--- O-co-NH-(cH2)6-NH-co-~ ocH2cH2l--- OH
A water-soluble crystalline substance with a melting point m.p. of 45 C was obtained by reacting 77.5 parts by weight of a polyglycol with an aver-age molecular weight of 1,550 with 6.7 parts by weight of hexamethylene diiso-cyanate.
Example 6 Polyurethane of the formula H-~-(OCH2CH2~----O-CO-NH- ~ CH3-N~I-CO-~--(OCH2CH2~0H
A solution of 8.9 parts by weight of isophorone diisocyanate in 50 parts by volume of chloroform was added to a solution of 15 parts by weight of a ~.77~02 polyglycol with an average molecular weight of 300 in 50 parts by volume of chloroform, analogously to Example 1. After subsequently stirring the mixture a~ 50C for 2 hours, the chloroform was evaporated off in a rotary evaporator.
A slightly viscous liquid which was very readily soluble in water was obtained.
Refractive index nD = 1.4952.
Example 7 Polyurethane of the formula (VII) >~
~12Cl~2~ -C-NH- U C 2 4 35 77.5 parts by weight of a polyglycol with an average molecu~ar weight of 1,550 were reacted with 8.9 parts by weight of isophorone diisocyanate analo-gously to Example 1. The resulting polyurethane was a crystalline substance, which was readily soluble in water to give a 10 % strength solution. Melting point: m.p. = 56C.
Example 8 Polyurethane of the formula (OCH2CH2~ o-co-NH- ~ c 2 4 2 68 A polyurethane which was soluble in water, giving a slightly turbid solution, and has a melting point m.p. of 47 C was obtained from 150 parts by weight of a polyglycol with an average molecular weight of 3,000 and 8.9 parts by weight of isophorone diisocyanate.
Example 9 Polyurethane of the formula -17- ~77402 Cil3 C113 (0c~l2cll2~-O-Co-NH- ~ CH2 2 2 2 68 102 parts by weight of a polyglycol with an average molecular weight of 3,000 were reacted with 5 parts by weight of isophorone diisocyanate as des-cribed in Example l. A crystalline substance which was very readily soluble in water and had a melting point m.p. of 54C was obtained.
Example 10 Polyurethane of the formula (XI) ~l ~ l3 H-~-~OCH2CH2~ 0-C0-NH- ~ 2 7 7 A slightly viscous li~uid which was readily soluble in water and had a refractive index nD of 1.4968 was obtained by reacting 24 parts by weight of a polyglycol with an average molecular weight of 300 with 15.5 parts by weight of isophorone diisocyanate in chloroform and evaporating off the solvent in a rotary evaporator.
Example 11 Polyurethane of the formula ~1 ~ (oc~l2cH2~ O-cO-NH-~c~l2)6-NH-co-t~-~ocH2cH2~ OH
After reacting 120 parts by weight of a polyglycol with an average molecular weight of 3,000 with 4.5 parts by weight of hexamethylene diisocyanate in methylene chloride, and after evaporating off the solvent in vacuo, a crystal-line substance which was readily soluble in water and had a melting point m.p.of 55C was obtained.
Example 12 Polyurethane of the formula ~IX) , .
-18- 1~4~
(OCH2cil2~---o-co-NH- ~ 2 2 35 93 parts by weight of a polyglycol with an average molecular weight of 1,550 and 8.9 parts by weight of isophorone diisocyanate were reacted with one another in chloroform. After evaporating off the solvent in vacuo, a crystal-line substance which was readily soluble in water was obtained. Malting point:
m.p. = 49C.
Example 13 Polyurethane of the formula ~X) H-(OCH2CH2~--- O-CO-NH- ~ CHH3-NH-CO-(OCH2CH2- } OH
124 parts by weight of a polyglycol with an average molecular weight of 1,550 and 8.9 parts by weight of isophorone diisocyanate were reacted with one another in chloroform. After evaporating off the solvent, a crystalline sub-stance which could readily be dissolved in water was obtained. Melting point:
m.p. - 56C.
Example 14 Polyurethane of the formula (XIV) H-~-(OCI~I-C~12~--0CH2-CH-CH2-CH2-0-(CH2CH-O~--CONH- ~ CH23 CH3 S03Na CH3 . _ lNH-CO ~ (OCHCH2 ~ 0-CH2-CIH-CH2-CH2 O-(CH2C~I-O ~ H
CH3 S03Na CH3 -19- ~774VZ
254 parts by weight of the sulphonate-diol of the formula H-(OCHCH23-- 0CH2-CH-CH2-CH2-0-~
CH3 S03Na CH3 were dissolved in 500 parts by volume of toluene, and the solution was warmed tothe reflux temperature. 83 parts by weight of isophorone diisocyanate were then added slowly. After subsequently stirring the mixture for 2 hours, the toluene was distilled off in vacuo. A crystalline substance which was readily soluble in water was obtained.
,d~
' ' ' ~ ' ' "'' -
Claims (30)
PROPERTY OR PRIVILEGE IS Claimed ARE DEFINED AS FOLLOWS:
1. A pharmaceutical composition containing as an active ingredient a water-soluble addition product of a polyetherdiol and a diisocyanate having a molecular weight in the range from 1,000 to 30,000, in the form of a sterile and/or physiologically isotonic aqueous solution or in the form of tablets.
2. A composition according to claim 1, in which the active ingredient is a water-soluble oligo-urethane or polyurethane of the general formula in which Q denotes a polyether radical which optionally contains ionic groups, the groups B are identical or different and denote a hydrogen atom or an aliphatic, alicyclic or aromatic radical with up to 8 carbon atoms or a X-CO-group in which X denotes a hydrogen atom or an aliphatic, alicyclic or aromatic radical with up to 7 carbon atomsi or a Y-O-CO- group, in which Y denotes an aliphatic, cycloaliphatic or aromatic radical with up to 7 carbon atoms, or a Z-NH-CO- group, in which Z denotes a hydrogen atom or an aliphatic, cycloali-phatic or aromatic radical with up to 7 carbon atoms, R denotes a bivalent radical of a diisocyanate, and m denotes a number from 1 to 30.
3. A composition according to claim 2, in which Q denotes a radical of the general formula in which A denotes hydrogen or methyl in random distribution and n denotes a number from 5 to 500.
4. A composition according to claim 3, in which n is a number from 8 t0 300.
5. A composition according to claim 2, 3 or 4, in which the groups B are identical or different and denote a hydrogen atom, a C1 to C4 alkyl group, a X-CO- group (in which X denotes a hydrogen atom or a C1 to C3 alkyl group), a Y-O-CO- group (in which Y denotes a C1 to C4 alkyl group) or a Z-NH-CO- group (in which Z denotes a hydrogen atom or a C1 to C4 alkyl group).
6. A composition according to claim 1, in which the active ingredient is a water-soluble polyaddition product of a polyethylene glycol and a diisocyanate, of the general formula in which R denotes a bivalent radical of a diisocyanate, m denotes a number from 1 to 30 and n denotes a number from 5 to 500.
7. A composition according to claim 2, 3 or 4 in which R denotes a bivalent radical of the diisocyanate which is derived from hexamethylene diisocyanate.
8. A composition according to claim 2, 3 or 4, in which the groups B are identical or different and denote a hydrogen atom, a C1 to C4 alkyl group, a X-CO- group (in which X denotes a hydrogen atom or a C1 to C3 alkyl group), a Y-O-CO- group (in which Y denotes a C1 to C4 alkyl group) or a Z-NH-CO- group tin which Z denotes a hydrogen atom or a C1 to C4 alkyl group), and in which R denotes a bivalent radical of the diisocyanate which is derived from hexa-methylene diisocyanate.
9. A composition according to claim 6 in which R denotes a bivalent radical of the diisocyanate which is derived from hexamethylene diisocyanate.
10. A composition according to claim 2, 3 or 4, in which R denotes a bivalent radical of the diisocyanate which is derived from isophorone diiso-cyanate.
11. A composition according to claim 2, 3 or 4, in which the groups B are identical or different and denote a hydrogen atom, a C1 to C4 alkyl group, a X-CO- group (in which X denotes a hydrogen atom or a C1 to C3 alkyl group), a Y-O-CO- group (in which Y denotes a C1 to C4 alkyl group) or a Z-NH-CO- group (in which Z denotes a hydrogen atom or a C1 to C4 alkyl group), in which R
denotes a bivalent radical of the diisocyanate which is derived from isophorone diisocyanate.
denotes a bivalent radical of the diisocyanate which is derived from isophorone diisocyanate.
12. A composition according to claim 6, in which R denotes a bivalent radical of the diisocyanate which is derived from isophorone diisocyanate.
13. A composition according to claim 1, in which the water-soluble addition product of a polyetherdiol and a diisocyanate carries ionic groups.
14. A composition according to claim 13, in which the water-soluble addition product is prepared from a polyetherdiol, which contains sulphonate groups, and a diisocyanate.
15. A composition according to claim 14, in which hexamethylene diiso-cyanate is used as the diisocyanate for the preparation of the water-soluble addition product carrying ionic groups.
16. A composition according to claim 14, in which isophorone diisocyanate is used as the diisocyanate for the preparation of the water-soluble addition product carrying ionic groups.
17. A composition according to claim 1 wherein the active ingredient is a water-soluble polyurethane of formula
18. A composition according to claim 1 wherein the active ingredient is a polyurethane of formula
19. A composition according to claim 1 wherein the active ingredient is a polyurethane of formula
20. A composition according to claim 1 wherein the active ingredient is a polyurethane of the formula
21. A composition according to claim 1 wherein the active ingredient is a polyurethane of the formula
22. A composition according to claim 1 wherein the active ingredient is a polyurethane of formula
23. A composition according to claim 1 wherein the active ingredient is a polyurethane of formula
24. A composition according to claim 1 wherein the active ingredient is a polyurethane of formula
25. A composition according to claim 1 wherein the active ingredient is a polyurethane of formula
26. A composition according to claim 1 wherein the active ingredient is a polyurethane of formula
27. A composition according to claim 1 wherein the active ingredient is a polyurethane of formula
28. A composition according to claim 1 wherein the active ingredient is a polyurethane of formula
29. A composition according to claim 1 wherein the active ingredient is a polyurethane of formula
30. A composition according to claim 1 wherein the active ingredient is a polyurethane of formula
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19803026575 DE3026575A1 (en) | 1980-07-12 | 1980-07-12 | ANTITUMORAL AGENTS |
| DEP3026575.9 | 1980-07-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1177402A true CA1177402A (en) | 1984-11-06 |
Family
ID=6107113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000381518A Expired CA1177402A (en) | 1980-07-12 | 1981-07-10 | Agents having a tumour-inhibiting action and their use |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0043974B1 (en) |
| JP (1) | JPS5748916A (en) |
| AT (1) | ATE8014T1 (en) |
| AU (1) | AU543561B2 (en) |
| CA (1) | CA1177402A (en) |
| DE (2) | DE3026575A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989007117A1 (en) * | 1988-02-01 | 1989-08-10 | Tyndale Plains-Hunter, Ltd. | Thermally reversible polyurethane hydrogels and cosmetic, biological and medical uses |
| US5276182A (en) * | 1990-07-09 | 1994-01-04 | The Dow Chemical Company | Process for preparing polyurea oligomers |
| DE4109668A1 (en) * | 1991-03-23 | 1992-09-24 | Bayer Ag | ISOCYANATE-FREE OLIGOMER URETHANE RESIN |
| US5424063A (en) * | 1992-01-09 | 1995-06-13 | The Dow Chemical Company | Narrow poly- and mono-dispersed anionic oligomers, and their uses, formulations and process |
| DE4225045A1 (en) * | 1992-07-29 | 1994-02-03 | Basf Ag | Use of water-soluble or water-dispersible polyurethanes as auxiliaries in cosmetic and pharmaceutical preparations and polyurethanes which contain copolymerized polylactic acid polyols |
| NZ254646A (en) * | 1992-08-19 | 1997-06-24 | Merrell Dow Pharma | Inhibition of angiogenesis by administration of a polyamide and a polyurea |
| JPH0753663A (en) * | 1993-07-30 | 1995-02-28 | Takiron Co Ltd | Base polymer for percutaneous absorption preparation |
| US5384119A (en) * | 1993-08-12 | 1995-01-24 | Merrell Dow Pharmaceuticals Inc. | Method of preventing neutrophil mediated connective tissue damage |
| FR2907678B1 (en) | 2006-10-25 | 2012-10-26 | Oreal | KERATIN FIBER COLORING COMPOSITION COMPRISING POLYSILOXANE / POLYUREE BLOCK COPOLYMER |
-
1980
- 1980-07-12 DE DE19803026575 patent/DE3026575A1/en not_active Withdrawn
-
1981
- 1981-06-30 EP EP81105042A patent/EP0043974B1/en not_active Expired
- 1981-06-30 DE DE8181105042T patent/DE3164296D1/en not_active Expired
- 1981-06-30 AT AT81105042T patent/ATE8014T1/en active
- 1981-07-01 AU AU72453/81A patent/AU543561B2/en not_active Ceased
- 1981-07-10 CA CA000381518A patent/CA1177402A/en not_active Expired
- 1981-07-10 JP JP56107228A patent/JPS5748916A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU543561B2 (en) | 1985-04-26 |
| AU7245381A (en) | 1982-01-21 |
| EP0043974A2 (en) | 1982-01-20 |
| ATE8014T1 (en) | 1984-07-15 |
| DE3164296D1 (en) | 1984-07-26 |
| EP0043974B1 (en) | 1984-06-20 |
| DE3026575A1 (en) | 1982-02-04 |
| JPS5748916A (en) | 1982-03-20 |
| EP0043974A3 (en) | 1982-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5548035A (en) | Biodegradable copolymer as drug delivery matrix comprising polyethyleneoxide and aliphatic polyester blocks | |
| US4495174A (en) | Anesthetic polyorganophosphazenes | |
| CA1177402A (en) | Agents having a tumour-inhibiting action and their use | |
| KR100546983B1 (en) | Polyethylene glycol-polyorthoester, polyethylene glycol-polyorthoester-polyethylene glycol, and polyorthoester-polyethylene glycol-polyorthoester block copolymers | |
| JP5008783B2 (en) | Prodrugs based on high molecular weight polymers | |
| US20080112918A1 (en) | Method for treating gout and binding uric acid | |
| AU2006230247A1 (en) | PEG-polyacetal and PEG-polyacetal-POE graft copolymers and pharmaceutical compositions | |
| US20020187121A1 (en) | Method for lowering serum glucose | |
| EP0187844A1 (en) | Polymeric iron chelators | |
| US20020187120A1 (en) | Method for treating gout and reducing serum uric acid | |
| US20050031575A1 (en) | Block copolymers | |
| JPS6136494B2 (en) | ||
| WO2015138566A1 (en) | Amino-bis-phosphonate-containing polymers via raft polymerization and based on linear polyethyleneimine | |
| Ferruti et al. | Effects of a series of new synthetic high polymers on cancer metastases | |
| CN107001603A (en) | water-soluble polycarbonate for medical applications | |
| US4064234A (en) | Methods and pharmaceutical preparation for the treatment of hypercholesterolemia | |
| EP0616813B1 (en) | Antitumor mitoxantrone polymeric compositions | |
| EP0044959A1 (en) | Anti-tumor agent | |
| US4440892A (en) | Agents having a tumor-inhibiting action and their use | |
| US4636387A (en) | Anesthetic polyorganophosphazenes | |
| US10179173B2 (en) | Semi-solid delivery systems | |
| US10226534B2 (en) | Semi-solid delivery systems | |
| CA1177404A (en) | Agents having a tumour-inhibiting action and their use | |
| CN116966199A (en) | Application of sulfoxide group-containing polymer in preparation of medicines for resisting postoperative tumor recurrence and/or inhibiting tumor metastasis | |
| US20170129970A1 (en) | Improved poppet for cryogenic fluid coupling |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |